Gamble Jones Investment Counsel lifted its stake in shares of Colgate-Palmolive (NYSE:CL) by 3.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,257 shares of the company’s stock after purchasing an additional 761 shares during the quarter. Gamble Jones Investment Counsel’s holdings in Colgate-Palmolive were worth $1,981,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its position in shares of Colgate-Palmolive by 8.4% during the 2nd quarter. Pacer Advisors Inc. now owns 20,224 shares of the company’s stock worth $1,499,000 after buying an additional 1,566 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Colgate-Palmolive during the 3rd quarter worth $1,814,000. Fiduciary Trust Co. raised its position in Colgate-Palmolive by 1.6% in the second quarter. Fiduciary Trust Co. now owns 170,818 shares of the company’s stock valued at $12,663,000 after purchasing an additional 2,758 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Colgate-Palmolive by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 1,131,987 shares of the company’s stock valued at $83,914,000 after purchasing an additional 105,878 shares during the last quarter. Finally, Pensionfund DSM Netherlands bought a new position in Colgate-Palmolive in the third quarter valued at about $4,225,000. 72.85% of the stock is currently owned by institutional investors.
Several equities analysts have commented on the company. Citigroup increased their target price on Colgate-Palmolive from $75.00 to $80.00 and gave the company a “neutral” rating in a research report on Tuesday, January 30th. Jefferies Group reiterated a “hold” rating and issued a $79.00 target price on shares of Colgate-Palmolive in a research report on Friday, January 26th. BNP Paribas downgraded Colgate-Palmolive from an “outperform” rating to an “underperform” rating in a research report on Tuesday, January 30th. Zacks Investment Research downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating in a research report on Monday, January 15th. Finally, Morgan Stanley dropped their target price on Colgate-Palmolive from $84.00 to $83.00 and set an “overweight” rating for the company in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $77.71.
In other news, insider Jennifer Daniels sold 7,375 shares of Colgate-Palmolive stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $73.18, for a total value of $539,702.50. Following the completion of the transaction, the insider now directly owns 38,691 shares in the company, valued at $2,831,407.38. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ellen M. Hancock sold 4,676 shares of Colgate-Palmolive stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $74.12, for a total value of $346,585.12. Following the completion of the transaction, the director now owns 208,063 shares of the company’s stock, valued at $15,421,629.56. The disclosure for this sale can be found here. Over the last quarter, insiders sold 414,019 shares of company stock valued at $29,541,377. 1.02% of the stock is owned by company insiders.
Colgate-Palmolive (CL) opened at $69.62 on Thursday. The firm has a market capitalization of $61,730.80, a price-to-earnings ratio of 30.54, a PEG ratio of 2.60 and a beta of 0.75. Colgate-Palmolive has a 52-week low of $67.52 and a 52-week high of $77.91. The company has a debt-to-equity ratio of 24.42, a current ratio of 0.47 and a quick ratio of 0.34.
Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, January 26th. The company reported $0.75 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.75. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Colgate-Palmolive had a return on equity of 1,716.69% and a net margin of 13.10%. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 earnings per share. analysts anticipate that Colgate-Palmolive will post 3.18 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Tuesday, January 23rd will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.30%. The ex-dividend date is Monday, January 22nd. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 70.18%.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.